Education
About Us
Working with TipRanks
Follow Us
Denali Therapeutics (DNLI)
NASDAQ:DNLI
DNLI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$13.67 - $33.33
Previous CloseN/A
Volume399.31K
Average Volume (3M)1.15M
Market Cap
$2.01B
Enterprise Value$2.69B
Total Cash (Recent Filing)$77.12M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.34
Next Earnings
May 13, 2025EPS Estimate
-0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.58
Shares Outstanding145,215,400
10 Day Avg. Volume955,234
30 Day Avg. Volume1,148,950
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.68
Price to Cash Flow (P/CF)-6.30
P/FCF Ratio0.00
Enterprise Value/Market Cap1.34
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit8.57
Enterprise Value/Ebitda-5.42
Forecast
1Y Price Target
$37.86Price Target Upside174.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
---
Bulls Say, Bears Say
Bulls Say
FDA SupportThe FDA's START program support might accelerate the approval pathway for DNL-126, which currently lacks standard therapy options.
Financial StabilityDenali has cash of approximately $1.2 billion, which should take the company into 2028.
Platform PositioningDenali Therapeutics is ideally positioned with its enzyme transport vehicle (ETV) platform.
Bears Say
CompetitionCompetitive Sanfilippo drug, RARE's UX111, could gain significant market share ahead of any DNL126 launch upon a successful outcome.
Price Target AdjustmentReevaluation of operational expenses and penetration assumptions for DNL310 results in a reduced price target from $87 to $80.
Trial ResultsDNL343 did not demonstrate a treatment effect on neurofilament light (NfL), a biomarker of neuronal damage.
---
Ownership Overview
9.11% Insiders
32.60% Mutual Funds
30.32% Other Institutional Investors
13.01% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DNLI FAQ
What was Denali Therapeutics’s price range in the past 12 months?
Denali Therapeutics lowest stock price was $13.67 and its highest was $33.33 in the past 12 months.
What is Denali Therapeutics’s market cap?
Denali Therapeutics’s market cap is $2.01B.
When is Denali Therapeutics’s upcoming earnings report date?
Denali Therapeutics’s upcoming earnings report date is May 13, 2025 which is in 46 days.
How were Denali Therapeutics’s earnings last quarter?
Denali Therapeutics released its earnings results on Feb 27, 2025. The company reported -$0.67 earnings per share for the quarter, beating the consensus estimate of -$0.799 by $0.129.
Is Denali Therapeutics overvalued?
According to Wall Street analysts Denali Therapeutics’s price is currently Undervalued.
Does Denali Therapeutics pay dividends?
Denali Therapeutics does not currently pay dividends.
What is Denali Therapeutics’s EPS estimate?
Denali Therapeutics’s EPS estimate is -0.7.
How many shares outstanding does Denali Therapeutics have?
Denali Therapeutics has 145,215,400 shares outstanding.
What happened to Denali Therapeutics’s price movement after its last earnings report?
Denali Therapeutics reported an EPS of -$0.67 in its last earnings report, beating expectations of -$0.799. Following the earnings report the stock price went down -10.968%.
Which hedge fund is a major shareholder of Denali Therapeutics?
Currently, no hedge funds are holding shares in DNLI
---
Denali Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$37.86 (174.15% Upside)
$37.86 (174.15% Upside)
Blogger Sentiment
Bullish
DNLI Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 354.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 2.3%
Last 30 Days ▲ 2.1%
Last 30 Days ▲ 2.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.53%
12-Months-Change
Fundamentals
Return on Equity
-37.40%
Trailing 12-Months
Asset Growth
19.09%
Trailing 12-Months
Company Description
Denali Therapeutics
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
---
DNLI Stock 12 Month Forecast
Average Price Target
$37.86
▲(174.15% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Biogen
―
Neurocrine
―
Vertex Pharmaceuticals
―
PTC Therapeutics
―
Best Analysts Covering DNLI
1 Year
1 Year Success Rate
5/11 ratings generated profit
1 Year Average Return
+27.86%
reiterated a buy rating 2 months ago
Copying Salveen Richter's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of +27.86% per trade.
---